HCV Treatment Advancements: Atea Pharmaceutical...

By João L. Carapinha

May 8, 2025

Atea Pharmaceuticals is hosting a virtual Hepatitis C virus (HCV) key opinion leader (KOL) panel on May 14, 2025. Experts will discuss challenges faced by HCV patients and results from Atea's Phase 2 study of bemnifosbuvir and ruzasvir. This panel...
South Africa NHI Bill Court Ruling Calls for Scrutiny
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Wegovy CVS Deal: Hybrid Market Access Strategy Insights
Empowering Health: The Role of Self-Care and NCDs in Global Health Policy
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure
Promising Results for Peanut Oral Immunotherapy
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...
Nipocalimab for Myasthenia Gravis Treatment
Trodelvy Keytruda Combination Delivers Breakthrough Results in Metastatic Tri...
Enhancing Pediatric Pain Management in Portuguese Emergency Departments: Prog...
AI Pediatric Sarcoma Diagnosis: Improving Speed and Accuracy in Cancer Classi...